{"entity":{"id":"volker-heinemann","kind":"person","name":"Volker Heinemann","aka":[],"tldr":"Gastrointestinal oncologist who led FIRE-3, a key trial of cetuximab versus bevacizumab in colorectal cancer.","summary":"Volker Heinemann is Director of the Comprehensive Cancer Center Munich at LMU Klinikum München and Professor of Medical Oncology. His specialisms are colorectal cancer, pancreatic ductal adenocarcinoma and anti-EGFR therapy. He led FIRE-3, the Lancet Oncology trial of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer, a key comparison that shaped the use of anti-EGFR therapy according to tumour sidedness. His record links him to the CRYSTAL and FIRE-3 trials, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Heinemann%20V%5BAuthor%5D%20FIRE-3"}],"tags":[],"related":[],"cancers":["colorectal","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["cetuximab","bevacizumab"],"companies":[],"institutions":["lmu-munich"],"pathways":[],"terms":[],"trials":["crystal-fire3"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Comprehensive Cancer Center Munich (LMU); Professor of Medical Oncology","institutionId":"lmu-munich","specialisms":["Colorectal cancer","Pancreatic cancer","Anti-EGFR therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Heinemann%20V%5BAuthor%5D%20FIRE-3"}],"papers":[{"title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3)","journal":"Lancet Oncology","year":2014,"doi":"10.1016/S1470-2045(14)70330-4"}]},"route":"/people/volker-heinemann/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"}],"institution":[{"id":"lmu-munich","kind":"institution","name":"LMU Klinikum München","route":"/institutions/lmu-munich/"}],"trial":[{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/"}],"paper":[{"id":"paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014","kind":"paper","name":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3)","route":"/key-papers/paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014/"},{"id":"paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017","kind":"paper","name":"Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials","route":"/key-papers/paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017/"},{"id":"paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017","kind":"paper","name":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","route":"/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/"}]}}